RECOMBINANT HUMAN SERUM ALBUMIN-COLLAGEN BINDING DOMAIN FUSION PROTEIN FOR TUMOR-SPECIFIC TARGETING MATRIX, AND USE THEREOF

Abstract: provided is a recombinant human serum albumin-collagen binding domain (cbd) fusion protein for tumor-specific targeting matrix and its use in specific targeted treatment of a solid tumor. hsa and the cbd generate gene fusion in the form of different molecular structures, and can be expressed in a constructed recombinant engineered host. a pharmaceutical recombinant fusion protein is obtained through large-scale fermentation. the recombinant fusion protein shows tumor-specific targeting of solid tumors and can be used as a starting material of a broad-spectrum matrix carrier. the recombinant fusion protein is coupled with any tumor treatment drug, small-molecule compound, or cytotoxic protein to form an innovative pharmaceutical composition. the pharmaceutical composition of the recombinant fusion protein is also long-acting, can prolong a half-life of the conjugate drug in vivo, and has a significantly better clinical curative efficacy on anti-tumor than that of a monomer drug.

Inventor(s): Yan FU, Dianxin LIU, Xiaonan YANG, Yusong FU, Fang HAN, Jingsheng YANG, Ying CHEN

CPC Classification: A61K47/64 (Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers ))

Search for rejections for patent application number 20250186598